Skip over navigation
Banner
Directory
Directory Search
Jobs
Job Search Post a Job
Patient
Patient Resources Drug Development
History
Genealogy
Toons & Teasers
Industry
 Directory
 Toons & Teasers
Quick Links
 Directory
 Job Search
 Toons & Teasers
 Advertising
 
Facilities
 

EquipNet Auction: Sell Your Surplus Equipment on Our Global Marketplace Now!

Our Newest Cartoon Illustrates: "Milestones in CRISPR"

North American Biotech Roadshow Featuring Grad Students, Post-Docs & Start-Up “Do’s & Don’ts”


Washington Life Science Industry Directory

Cervical Health Awareness Month

Banner Advertising

Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and delayed by COVID-19, to be launched in 2023 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved directory upon the launch of the new site. We apologize for the inconvenience.

NanoString Technologies, Inc.


NanoString Technologies, Inc.
530 Fairview Ave N, Suite 2000
Seattle, WA 98109
NanoString Technologies, Inc.
 
Phone: (206) 378-NANO
Fax: (206) 387-6288
Year Established:  2003
Employees: 90
Ticker: NSTG
Exchange: NASDAQ
Main Contact: David W. Ghesquiere, Senior VP, Corporate & Business Development
 
Other Contacts:  Alessandra Cesano, M.D., Ph.D., CMO
Kathy Surace-Smith, VP & General Counsel
J. Chad Brown, Senior VP, Sales & Marketing
Thomas Bailey, CFO
Joseph M. Beechem, Ph.D., Senior VP, R&D
Mary Tedd Allen, Ph.D., Senior VP, Operations
Brad Gray, President & CEO
 
Company Description
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.


Main Industry Directory

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 1997 - 2023 Info.Resource, Inc. All rights reserved.
Privacy Policy . Cookie Policy . Terms of Use . About . Advertising

WashingtonLifeScience.com is owned and published by Info.Resource, Inc.